Facebook
X
LinkedIn
ForwardLooking to the Future: Novel Targets
In this session, expert speakers will discuss the future of theranostics. The speakers pay specific attention to the following topics: novel cancer-specific targets, novel pan-cancer targets, and the potential use of alpha emitters. This session focuses on current preclinical work and clinical trials in progress.
Target Audience
This meeting was designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, radiation therapists, radiation dosimetrists, specialists, nuclear physicians and practice administrators.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Identify novel cancer-specific targets for theranostics.
- Understand the potential of pan-cancer targets in theranostics.
- Learn the differences between different alpha emitters, and challenges with implementation.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.